Results 51 to 60 of about 20,576 (195)

Real‐world outcomes of aflibercept 8 mg in patients previously treated for neovascular age‐related macular degeneration

Acta Ophthalmologica, Volume 104, Issue 3, Page 296-304, May 2026.
Abstract Purpose To evaluate visual, anatomical and safety outcomes of aflibercept 8 mg in previously treated patients with neovascular age‐related macular degeneration (nAMD). Methods This retrospective study included nAMD patients switched to aflibercept 8 mg from prior anti‐VEGF therapies at Sahlgrenska University Hospital between February 2024 and ...
Imadeddin Abu Ishkheidem, Esra Inci, Martin Breimer, Sofia Töyrä Silfverswärd, Madeleine Zetterberg, Marita Andersson Grönlund   +5 more
wiley   +1 more source

Characteristics and racial variations of polypoidal choroidal vasculopathy in tertiary centers in the United States and United Kingdom [PDF]

, 2017
PURPOSE: To evaluate the characteristics and racial variations amongst patients with polypoidal choroidal vasculopathy (PCV) in the United States and the United Kingdom.
Adelman, RA, Alasil, T, Baumal, CR, Coady, PA, de Carlo, TE, Duker, JS, Keane, PA, Munoz, N, Novais, E, Tufail, A, Waheed, NK   +10 more
core   +1 more source

Neovascular age‐related macular degeneration without drusen

Acta Ophthalmologica, Volume 104, Issue 3, Page e300-e311, May 2026.
Abstract Purpose To describe the clinical characteristics and 1‐year follow‐up of patients with neovascular AMD (nAMD) without drusen in either eye. Methods This is a multicentre retrospective cohort study in three tertiary referral centres in The Netherlands. We included patients of 55 years or older with nAMD in one or both eyes, without the presence
Marc J. Sirks, Elon H. C. van Dijk, Husein Ghalayini, Somayeh Bazdar, WeiFeng Yu, Suzanne Yzer, José P. Martinez Ciriano, Reinier O. Schlingemann, Roselie M. H. Diederen, Camiel J. F. Boon   +9 more
wiley   +1 more source

Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review [PDF]

, 2014
As increased angiogenesis has been linked with the progression of ovarian cancer, a number of anti-angiogenic agents have been investigated, or are currently in development, as potential treatment options for patients with advanced disease.
Dimitrios Pectasides, Gerasimos Aravantinos   +1 more
core   +1 more source

Attenuation of Oxygen‐Induced Neovascularization and Inflammation by Neutralizing VEGFA and/or ANG‐2 With an Antibody

Genes to Cells, Volume 31, Issue 3, May 2026.
The effects of intraocular administration of neutralizing antibodies against VEGFA, ANG‐2, or bispecific to these two factors on pathological findings were examined in the oxygen‐induced retinopathy (OIR) mouse model. The antibody to VEGFA or ANG‐2 attenuated oxygen‐induced neovascularization and inflammation, and the bispecific antibody more ...
Hirokazu Oohashi, Toshiro Iwagawa, Hiroto Abe, Chihiro Kawaji, Yuta Inokuchi, Tetsuhiro Soeda, Kosuke Saita, Makoto Aihara, Sumiko Watanabe   +8 more
wiley   +1 more source

Cost-effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration and its Subtypes from the Societal and Patient Perspectives in Japan

Ophthalmology and Therapy
Introduction This study evaluated the cost-effectiveness of anti-vascular endothelial growth factor (VEGF) therapies for subtypes of neovascular age-related macular degeneration (nAMD) from the societal perspective, and for any nAMD from the patient ...
Yasuo Yanagi, Kanji Takahashi, Tomohiro Iida, Fumi Gomi, Hiroshi Onishi, Junko Morii, Taiji Sakamoto   +6 more
doaj   +1 more source

Intravitreal Aflibercept as a Rescue Therapy for Retinal Neovascularization and Macular Edema due to Eales Disease

Case Reports in Ophthalmological Medicine, 2021
We report the rescue effect of intravitreal aflibercept injections on retinal neovascularization and macular edema due to Eales disease. Case 1 was a 36-year-old female. Intravitreal aflibercept was administered as rescue therapy after persistent retinal
Ning-Yi Hsia, Chun-Ju Lin, Chun-Ting Lai, Henry Bair, Cheng-Hsien Chang, Jane-Ming Lin, Yi-Yu Tsai   +6 more
doaj   +1 more source

Ropivacaine vs tetracaine in topical anesthesia for intravitreal injection [PDF]

, 2015
Aim: The object of the study was to evaluate the long term efficacy and safety of ropivacaine 0,5% vs tetracaine 0,5% for topical anesthesia in intravitreal injection of dexamethasone in patients with diabetic macular edema (DME) and anti-vascular ...
COLLINI, Saul, PACELLA, Elena, PACELLA, FERNANDA, SALDUCCI, Mauro, SMALDONE, GIANPAOLO, Troisi, Fabiana, TURCHETTI, PAOLO   +6 more
core   +1 more source

Biopharmaceuticals for Cancer Treatment: An Update

Cancer Medicine, Volume 15, Issue 4, April 2026.
ABSTRACT Cancer is one of the most debilitating diseases, causing profound physical and psychological impacts on patients. The global number of cancer patients has been steadily rising over the last few decades. The development of effective cancer therapies remains the primary focus in life science research, requiring a precise understanding of ...
Anupom Deb Nath, Yousuf Alam, Afsana Mustak Mim, Maksuda Akter, Mohammad Abbas Gani, Khondaker Muhammad Khairul Alam, Md. Nur Alam   +6 more
wiley   +1 more source

Relevance of indirect comparisons in the German early benefit assessment and in comparison to HTA processes in England, France and Scotland [PDF]

, 2014
Early benefit assessment in Germany under the legislative framework of AMNOG (Arzneimittelmarktneuordnungsgesetz) requires direct comparisons of the new drug with appropriate comparators determined by the Federal Joint Committee (G-BA).
Dippel, Franz-Werner, Gasche, David, Lebioda, Andrea, Plantör, Stefan, Theobald, Karlheinz   +4 more
core   +4 more sources